Houston, TX – M D Anderson Medical Center

Melanoma Clinical Trials- Recruiting

Phase
NCT00454701
Assessment and Tracking of Long-term Alefacept Safety		 Phase IV
NCT00297895
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)		 Phase III
NCT00911326
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma		 Phase III
NCT00116363
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma		 Phase II
NCT01092728
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma		 Phase II
NCT01266967
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain		 Phase II
NCT01413191
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye		 Phase II
NCT01119508
Ipilimumab + Temozolomide in Metastatic Melanoma		 Phase II
NCT01200342
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma		 Phase II
NCT00539591
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma		 Phase II
NCT01064713
Phase II Study of Tesetaxel in Metastatic Melanoma		 Phase II
NCT01092585
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH		 Phase II
NCT00506142
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma		 Phase II
NCT00338377
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization		 Phase II
NCT01136967
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma		 Phase II
NCT01266603
High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI		 Phase II
NCT00960752
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist		 Phase II
NCT00940225
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies		 Phase II
NCT01340729
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma		 Phase I, Phase II
NCT01409174
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma		 Phase I, Phase II
NCT01409187
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma		 Phase I, Phase II
NCT01067066
A Phase I/II Study of TPI 287 – Temozolomide Combination in Melanoma		 Phase I, Phase II
NCT01217411
RO4929097 And Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer		 Phase I, Phase II
NCT01337765
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients		 Phase I, Phase II
NCT00861406
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine		 Phase I
NCT00386906
Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma		 Phase I
NCT01010984
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma		 Phase I
NCT01295931
Nuclear and Near-Infrared (NIR) Imaging in Melanoma		 Phase I
NCT00304525
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma		 Phase I
NCT00833807
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver		 Phase I
NCT01127594
Evaluate Safety/Tolerability of Intra-Arterial Temozolomide for Patients w/ Advanced Extremity Melanoma Using Isolated Limb Infusion (ILI)		 Phase I
NCT00121680
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma		 Phase I
NCT01039844
Study of Weekly LOC-paclitaxel Injection for Melanoma		 Phase I
NCT01294735
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014)		 Phase I
NCT01072175
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212		 Phase I
NCT01183663
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)		 Phase I
NCT00861406
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine		 Phase I
NCT00386906
Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma		 Phase I
NCT01010984
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma		 Phase I
NCT01295931
Nuclear and Near-Infrared (NIR) Imaging in Melanoma		 Phase I
NCT00507325
Sample Collection From Melanoma Patients
NCT00828126
PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma
NCT00495950
Prospective Measurement of Post-Treatment Lymphedema
NCT01311843
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
NCT00897442
Collecting Tumor Samples From Patients With Gynecological Tumors
NCT01193036
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
NCT01412749
TEST: Registry for Endoscopic Head and Neck Surgery
NCT01237457
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Updated from clinicaltrials.gov on 8/24/2011

Comments are closed.